Cedars-Sinai investigators have discovered that large oncosomes—fluid-filled sacs released into the bloodstream by aggressive ...

Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory ...

The incidence of neuroendocrine tumors is increasing, necessitating the need for more post-operative medical strategies. Available therapies and promising agents are discussed in this article.

Exelixis stock shines with 36% CABOMETYX sales growth, promising zanzalintinib market expansions, and raised 2025 guidance.

Bruna was subsequently prescribed antidepressants, but despite her condition steadily worsening, her concerns were repeatedly ...

A student has shared her experience of being repeatedly dismissed by doctors, despite losing 10 kilos in just two months and ...

CHICAGO — In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 WaveLINE-003 trial of patients with relapsed/refractory diffuse B-cell lymphoma ...

Large cell neuroendocrine carcinoma of the prostate is an extremely rare malignant subgroup with limited reported cases. Little is known about its pathological characteristics, treatment options and ...

Due to cancer cells being another example of mesenchymal cells, studying how these cells move and communicate could also help scientists learn how tumors grow and spread.

SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer ...

Abnormal amino acid metabolism supports cancer cell proliferation, invasion, and immune evasion in hepatocellular carcinoma (HCC). Previous research exploring amino acid metabolism in HCC has ...

Genmab A/S today announced new results from the Phase 1 b/2 EPCORE ® NHL-2 trial Arm 10, evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination ...